WO2001036398A1 - Benzoxa- and benzthiazoles - Google Patents

Benzoxa- and benzthiazoles Download PDF

Info

Publication number
WO2001036398A1
WO2001036398A1 PCT/EP2000/011475 EP0011475W WO0136398A1 WO 2001036398 A1 WO2001036398 A1 WO 2001036398A1 EP 0011475 W EP0011475 W EP 0011475W WO 0136398 A1 WO0136398 A1 WO 0136398A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
alkyl
free form
benzoxazol
Prior art date
Application number
PCT/EP2000/011475
Other languages
French (fr)
Inventor
Andreas Billich
Erwin Paul Schreiner
Barbara Wolff-Winiski
Original Assignee
Novartis Ag
Novartis Erfindungen Verwaltungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927439.1A external-priority patent/GB9927439D0/en
Priority claimed from GB0007511A external-priority patent/GB0007511D0/en
Application filed by Novartis Ag, Novartis Erfindungen Verwaltungsgesellschaft Mbh filed Critical Novartis Ag
Priority to US10/130,567 priority Critical patent/US6716865B1/en
Priority to AT00981270T priority patent/ATE269853T1/en
Priority to EP00981270A priority patent/EP1230227B1/en
Priority to DE60011801T priority patent/DE60011801T2/en
Priority to JP2001538887A priority patent/JP2003514806A/en
Priority to AU18577/01A priority patent/AU1857701A/en
Publication of WO2001036398A1 publication Critical patent/WO2001036398A1/en
Priority to HK02109307.7A priority patent/HK1049329B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the invention relates to benzoxa- and benzthiazole derivatives. It concerns a benzoxa- or benzthiazole substituted at the 2 position and carrying a sulfamic acid ester group bound via oxygen to the phenyl part of the ring structure, hereinafter briefly named "a compound of the invention”.
  • X is O or S
  • Ri and R 2 either independently are hydrogen or alkyl, or one is hydrogen and the other is acyl or alkoxycarbonyl; and R 3 is alkyl; alkenyl; alkinyl; cycloalkyl; cycloalkenyl; aryl; acyl; cycloalkylalkyl; cycloalkylalkenyl, including cycloalkanylidenealkyl; cycloalkenylalkyl; arylalkyl; arylalkenyl; arylalkinyl; alkoxycarbonylaminoalkyl; hydroxycycloalkylalkyl; cycloalkanylidenec'ycloalkanylidenalkyl; heteroaryl; or heteroarylalkyl; in free form or salt form.
  • the sulfamoyloxy moiety in formula I is bound to the ring system in position 5 or 6, preferably 6.
  • Alkyl as a group Ri or R 2 preferably is of 1 to 4 carbon atoms, it especially is methyl.
  • Acyl as a group R ! or R 2 preferably is formyl or alkylcarbonyl of altogether 2 to 5 carbon atoms, it especially is acetyl.
  • Alkoxycarbonyl as a group Ri or R 2 preferably is of altogether 2 to 5 carbon atoms, it especially is methoxycarbonyl.
  • R 3 alkyl as such or as part of a substituent such as cycloalkylalkyl includes (C ⁇ . 22 )alkyl, e.g.
  • alkenyl as such or as part of a substituent such as cycloalkylalkenyl includes (C 2 . 22 )alkenyl, e.g.
  • alkinyl as such or as part of a substituent such as arylalkinyl includes (C 2-22 )alkinyl; cycloalkyl as such or as part of a substituent such as cycloalkylalkyl or hydroxycycloalkylalkyl includes (C 4 . ⁇ 2 )cycloalkyl, such as cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclododecanyl; it may be mono- or polycyclic, such as bridged cycloalkyl, as in adam
  • a second cycloalkyl such as decalin (octahydronaphthyl), and includes spiro cycloalkyl, as in l,4-dioxa-spiro[4.5]decyl or l,5-dioxa-spiro[5.5]undecyl, whereby the cycloalkyl moiety and the annexed second ring system are unsubstituted or substituted with e.g up to 4, preferably one or two alkyl or alkoxy moieties of preferably 1 or 2 carbon atoms; when cycloalkyl is part of a substituent, there preferably is just one, but there may be up to two, mono- or polycyclic cycloalkyl moieties, as in e.g.
  • cycloalkenyl as such or as part of cycloalkenylalkyl includes (C 4 . ⁇ 2 )cycloalkenyl, such as cyclohexenyl; it may be polycyclic, as in e.g. decahydrophenanthrenyl, and may be substituted, e.g. with 1 to 3 (C ⁇ - 4 )alkyl; aryl as such or as part of arylalkyl, arylalkenyl or arylalkinyl includes (C 5 . ⁇ 8 )aryl, e.g. (C 5 - ⁇ 2 )aryl, e.g.
  • phenyl or tetrahydronaphthalinyl may be substituted by e.g. alkyl; there may be up to 3, preferably 1 aryl moiety when aryl is part of a substitutent, as in di- or triphenylmethyl;
  • acyl includes the residue of a carboxylic acid, in particular an alkyl, aralkyl or aryl carboxylic acid, e.g. an alkyl, aralkyl or aryl carbocyclic acid;
  • - cycloalkylalkenyl includes e.g. a cycloalkanylidenalkyl group of formula i
  • R is hydrogen or alkyL e.g. especially methyl
  • R 5 and R$ together with the carbon atom to which they are attached form cycloalkyl
  • - cycloalkenylalkyl is e.g. cyclohexenylmethyl
  • - alkoxycarbonylaminoalkyl is e.g. tert-butoxycarbonylamino-2,2-dimethylpropyl;
  • the hydroxy group preferably is bound to the cycloalkyl part at the same carbon atom that is bound to the alkylene part of the hydroxycycloalkylalkyl moiety;
  • - cycloalkanylidenecycloalkanylidenalkyl is e.g. bicyclobutylidenylidenemethyl
  • heteroaryl as such or as part of heteroarylalkyl preferably is pyridyl or thienyl.
  • X preferably is oxygen.
  • Ri and R 2 preferably are hydrogen.
  • R 3 preferably is alkyl; cycloalkylalkyl; cycloalkenylalkyl; alkoxycarbonylaminoalkyl; or cycloalkylalkenyl, e.g. a group of formula i as defined above.
  • a subgroup of compounds of the invention is the compounds of formula I wherein X is as defined above; Ri and R 2 are hydrogen; and R 3 is alkyl, alkenyl, cycloalkyl or cycloalkenyl, in free form or salt form.
  • a further subgroup of compounds of the invention is the compounds of formula Is
  • X, Ri, R 2 and R 4 are as defined above; in free form or salt form; e.g. sulfamic acid 2-(adamantan-2-ylidenemethyl)benzoxazol-6-yl ester in free form or salt form.
  • a further subgroup of compounds of the invention is the compounds of formula Ipi
  • R ⁇ p and R 2p have the significances indicated above for Ri and R 2 ;
  • R 3p ⁇ is alkyl; alkenyl; alkinyl; cycloalkyl; acyl; cycloalkylalkyl; arylalkyl; arylalkenyl; arylalkinyl; heteroaryl; or heteroarylalkyl; or Ri p and R 2p are hydrogen; and R 3p ⁇ is adamantan-2-ylidenemethyl; in free form or salt form.
  • a further subgroup is the compounds of formula Ip 2
  • Ri and R 2 are as defined above;
  • R 3p2 is alkyl; alkenyl; alkinyl; cycloalkyl; acyl; cycloalkylalkyl; adamantylalkenyl, including adamantanylidenalkyl; arylalkyl; arylalkenyl; arylalkinyl; heteroaryl; or heteroarylalkyl; in free form or salt form.
  • a further subgroup is the compounds of formula Iq
  • - cycloalkyl selected from adamantyl and hexahydro-2-5-methano-pentalenyl;
  • - cycloalkyl selected from adamantylalkyl of 1 to 4 carbon atoms in the alkylene part thereof and dicyclohexylmethyl;
  • cycloalkylalkenyl (including cycloalkanylidenalkyl) selected from: adamantanyliden(C ⁇ -4 )alkyl; (C 4 . ⁇ 2 )cycloalkyliden(C ⁇ -4 )alkyl; bicyclo[3.3.
  • - arylalkyl selected from di- or triphenyl(C ⁇ _ 4 )alkyl
  • - hydroxycycloalkylalkyl selected from: (2-hydroxyadamant-2-yl)(C ⁇ -6 )alkyl; (9-hydroxybicyclo[3.3. l]non-9-yl(Ci_ )alkyl; and
  • cycloalkanylidenecycloalkanylidenalkyl moiety bicyclobutylidenylidenemethyl; in free form or salt form.
  • a compound of the invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a solvated salt.
  • a salt of a compound of the invention includes a pharmaceutically acceptable salt, e.g. an acid addition salt.
  • a compound of the invention in free form may be converted into a corresponding compound in the form of a salt and vice versa.
  • a compound of the invention in the form of a solvate in free form or salt form may be converted into a corresponding compound in free form or salt form in unsolvated form and vice versa.
  • a compound of the invention may exist in the form of isomers and mixtures thereof; e.g. a compound of the invention may contain substituents exhibiting geometric isomerism and/or asymmetrically substituted carbon atoms and may thus exist in the form of isomers and/or diastereoisomeres and mixtures thereof. Isomeric mixtures may be separated in conventional manner to obtain pure isomers or diastereoismers, respectively.
  • the invention includes a compound of the present invention in any isomeric and/or diasteroisomeric pure form and in the form of any isomeric and/or diastereoisomeric mixture.
  • the invention further includes a process for the preparation of a compound of the invention as defined above, comprising sulfamoylating a corresponding benzoxa- or benzthiazole substituted in the 2 position and carrying a hydroxy group on the phenyl part of the ring structure.
  • Process variant a) may be carried out e.g. by reacting a compound of formula II al) with sulfuryl chloride and sodium- or potassium azide, and reducing the azide group to an amino group -NH 2 in a resultant compound of formula III
  • Ri and R 2 are both hydrogen and L is a leaving group, e.g. halogen, preferably chloro; such as H 2 N-SO 2 Cl; e.g. in an inert solvent, e.g. dimethylformamide or dimethylacetamide, with or without addition of an organic base, such as an organic tertiary amine, or an inorganic base, e.g. an alkali(hydrogen)carbonate or alkali hydride, preferably sodium hydride.
  • halogen preferably chloro
  • an organic base such as an organic tertiary amine, or an inorganic base, e.g. an alkali(hydrogen)carbonate or alkali hydride, preferably sodium hydride.
  • Process variant b) may be effected by N-alkylating, N-acylating or N-alkoxycarbonylating using e.g. for N-alkylation activated alkyl, e.g. alkyl halogenides, such as alkyl iodides, alkyl sulfates or alkyl mesy(tosy)lates; for N-acylation acyl halogenides; and for N-alkoxycarbonylation alkoxycarbonyl halides, preferably chlorides.
  • N-alkylation activated alkyl e.g. alkyl halogenides, such as alkyl iodides, alkyl sulfates or alkyl mesy(tosy)lates
  • alkyl halogenides such as alkyl iodides, alkyl sulfates or alkyl mesy(tosy)lates
  • N-acylation acyl halogenides such as alkyl
  • the reaction is effected conveniently in the presence of a suitable base, preferably an alkali metal carbonate or alkali metal hydride, preferably in an inert, preferably polar solvent such as acetone or dimethylformamide, at temperatures between about -20° and about +120°C, preferably between room temperature and about 60°C.
  • a suitable base preferably an alkali metal carbonate or alkali metal hydride
  • an inert preferably polar solvent such as acetone or dimethylformamide
  • a resultant compound of the invention may be recovered from the reaction mixture and isolated and purified in conventional manner.
  • Isomers such as geometric isomers or enantiomers or diastereoisomers, may be obtained in conventional manner, e.g. by fractional crystallization or asymmetric synthesis from corresponding asymmetrically substituted, e.g. optically active starting materials.
  • the starting materials may also be prepared in conventional manner.
  • a compound of formula II may e.g. be obtained by ⁇ ) reacting a compound of formula V
  • R 5 and R « are as defined above, e.g. in the presence of trimethylsilyl chloride (TMSCl), N-ethyld ⁇ sopropylamine and sodium bis(trimethylsilyl)amide in an inert solvent, e.g. tetrahydrofurane, at low temperatures, e.g. around -70°C, and dehydrating a resultant compound of formula lie
  • TMSCl trimethylsilyl chloride
  • N-ethyld ⁇ sopropylamine N-ethyld ⁇ sopropylamine
  • sodium bis(trimethylsilyl)amide in an inert solvent, e.g. tetrahydrofurane
  • X, R 4 , R 5 and Re are as defined above, e.g. by treatment with trifluoroacetic acid in an inert solvent such as toluene.
  • Process variant a3) above is also indicated for the preparation of a compound of formula I wherein Ri and R 2 are hydrogen, X is as defined above and R 3 is a group of formula i as defined above, starting from a corresponding compound of formula lie and dehydrating a resultant compound of formula I wherein R 3 is hydroxycycloalkylalkyl as described under ⁇ ) above.
  • a compound of formula II may be obtained by reaction of a compound of formula V with a compound of formula R 3 COOH, conveniently in the presence of propylphosphonic acid anhydride and N-ethyl-diisopropylamine; or 2,2'-dithiopyridine and triphenylphosphane; preferably in an inert solvent, e.g. methylene chloride, and cyclizing a resultant compound of formula VII
  • X and R> are as defined above and Alk is alkyl, preferably methyl, with a compound of formula VI, e.g. in the presence of butyl lithium in an inert solvent, e.g. tetrahydrofurane, conveniently at low temperatures, such as around -70°C, to obtain a compound of formula IX
  • Alk, X, R ⁇ R 5 and R are as defined above; and either
  • Alk, X, > , R 5 and Re are as defined above; and then dealkylating to obtain a corresponding compound of formula Ila, e.g. in the presence of pyridine and HCl, conveniently at high temperatures, such as above about 100°C, e.g. around 200°C.
  • Examples la and lb Sulfamic acid 2-ri-(2-hydroxyadamantan-2-yl)pentvn- benzoxazol-6-yl ester and, respectively, sulfamic acid 2-ri-(adamantan-2-ylidene)pentyll- benzoxazol-6-yl ester
  • Example lb (125.8 MHz, de-DMSO) 166.091, 158.038, 149.590, 147.630, 119.957,
  • Example 8 166.745, 155.558, 150.600, 149.648, 147.269, 120.358, 119.394, 105.693, 64.292, 57.866, 35.634, 28.333, 26.318, 14.102.
  • Example 12 168.446, 146.658, 140.656, 119.420, 118.622, 105.099, 103.659, 41.770, 40.197, 39.233, 36.789, 33.951, 27.851.
  • Example 28 (125.8 MHz) 164.389, 160.842, 149.534, 146.796, 140.860, 119.638, 118.531, 110.406, 105.023, 38.294, 32.437, 30.581, 30.030, 22.869, 22.406, 13.866, 13.835.
  • Example 29 (125.8 MHz) 160.874, 146.784, 140.909, 119.643, 118.522, 110.396, 105.037, 38.574, 32.674, 31.955, 31.506, 28.017, 27.538, 22.460, 22.277, 13.919.
  • Example 30 (125.8 MHz) 160.924, 146.798, 140.770, 119.592, 118.590, 110.348, 105.036, 38.639, 32.736, 31.575, 29.427, 29.003, 28.333, 27.849, 22.529, 22.496, 14.006, 13.976.
  • Example 31 (125.8 MHz) 160.870, 146.764, 140.969, 119.653, 118.499, 110.392, 105.021, 38.609, 32.702, 31.736, 29.733, 29.298, 29.050, 28.378, 27.886, 22.614, 14.008.
  • Example 35 (125.8 MHz, ⁇ VDMSO) 167.336, 157.635, 154.176, 149.395, 132.640, 130.962, 123.041, 120.036, 118.927, 115.893.
  • Example 57 (d ⁇ -DMSO) 165.887, 162.639, 151.553, 147.166, 134.719, 122.842, 121.308, 115.533, 110.953, 40.749, 38.615, 36.358, 33.594, 27.502.
  • Starting materials and intermediates may be obtained as follows:
  • a mixture of 1.01 ml of pivaloyl chloride, 808 mg 2,4-d ydroxyaniline hydrochloride (formula V) and 0.4 ml of pyridine is heated at about 210° for about 18 hours.
  • the mixture obtained is dispersed in a mixture of cyclohexane and ethyl acetate and purified by chromatography.
  • the title compound is obtained (m.p. 204-210°).
  • the evaporation residue obtained is treated with 240 ml of toluene, 3.1 ml of trifluoroacetic acid are added, and the reaction mixture is heated at about 115° for about 7 hours and cooled. Crystallization occurs.
  • the first title compound above is obtained in the form of a ciystalline salt with trifluoroacetic acid. This is recrystallized in ethanol. The compound in free form is obtained (m.p. 248-253°).
  • 187 ul of methansulfonyl chloride are added to a mixture of 350 mg of 2-(5-methoxybenzothiazol-2-ylmethyl)cycloheptan-2-ol (formula IX), 665 ul of triethylamine and a catalytical amount of 4-N,N-d me ylaminopyridine in 12 ml of dry dichloromethane at about 0°.
  • the mixture is stirred for about 12 hours at room temperature, 187 ⁇ l of methansulfonyl chloride and 665 ⁇ l of triethylamine are added and the resultant reaction mixture is stirred at about 40° for about 48 hours.
  • the compounds of the invention in particular the compounds of formula I, in free form or pharmaceutically acceptable salt form, including as solvates, hereinafter briefly named "the agents of the invention", possess pharmacological activity. They are indicated for use as pharmaceuticals. In particular, they inhibit steroid sulfatase activity.
  • Steroidal hormones in particular tissues are associated with several diseases, such as tumors of the breast, endometrium and prostate.
  • Important precursors for the local production of these steroid hormones are steroid 3-O-sulfates which are desulfated by the enzyme steroid sulfatase in the target tissues. Inhibition of this enzyme results in therapeutically relevant, reduced local levels of the corresponding active steroidal hormones.
  • steroid sulfatase inhibitors may also be immunosuppressive, and enhance memory when delivered to the brain.
  • the agents of the invention reduce endogenous levels of androgens and/or estrogens in skin and are thus particularly indicated for use in the prevention or treatment of androgen-dependent disorders of the pilosebaceous unit, such as acne, seborrhea, androgenic alopecia and hirsutism, and in the topical treatment of squamous cell carcinoma.
  • the agents of the invention are therefore indicated for use as steroid sulfatase inhibitors, particularly in the prevention and treatment of illnesses responsive to steroid sulfatase inhibition, such as illnesses in which the steroid products of sulfatase cleavage play a role, in particular in the prevention and treatment of the following specific conditions: androgen- dependent disorders of the pilosebaceous unit such as acne, seborrhea, androgenic alopecia and hirsutism; cancer, especially estrogen- and androgen-dependent tumors such as tumors of the breast, endometrium and prostate, and squamous cell carcinoma; inflammatory and autoimmune diseases such as rheumatoid arthritis, type I and II diabetes, systemic lupus erythematosus, multiple sclerosis, myastenia gravis, thyroiditis, vasculitis, ulcerative colitis and Crohn's disease; skin disorders such as psoriasis, eczema and contact
  • Human steroid sulfatase is obtained in pure form as described in WO 99/52890 and the assay is effected as follows:
  • Purified human steroid sulfatase not only is capable of cleaving steroid sulfates, but also readily cleaves aryl sulfates, such as p-nitrocatechol sulfate which is used herein.
  • Assay mixtures are prepared by consecutively dispensing the following solutions into the wells of flat-bottom micro titer plates:
  • IC50 values are calculated by nonlinear regression of the concentration/optical density data using the program Grafit (Erithacus Ltd.). Reported values are the result of three determinations.
  • Estrone-3-O-sulfamate serves as reference compound and its IC50 value is determined in parallel to the test compounds and is about 60 nM.
  • Relative IC 50 values are defined as follows:
  • the agents of the invention inhibit steroid sulfatase in this assay with rel IC 50 values in the range of about 0.1 to 30.
  • CHO cells stably transfected with human steroid sulfatase are seeded into microtiter plates. After reaching approximately 90% confluency, they are incubated overnight with graded concentrations of test substances. They are then fixed with 4 % paraformaldehyde for 10 minutes at room temperature and washed 4 times with PBS before incubation with 100 ⁇ l/well 0.5 mM 4-methylumbelliferyl sulfate (MUS) dissolved in 0.1M Tris-HCl, pH 7.5. The enzyme reaction is carried out at 37°C for one hour. Then 50 ⁇ l/well stop solution (1M Tris-HCl, pH 10.4) are added.
  • MUS 4-methylumbelliferyl sulfate
  • the enzyme reaction solutions are transferred to white plates (Microfluor, Dynex, Chantilly, VA, USA) and read in a Fluoroskan II fluorescence microtiter plate reader. Reagent blanks are subtracted from all values.
  • the fluorescence units are divided by the optical density readings after staining cellular protein with sulforhodamine B (OD 550 ) in order to correct for variations in cell number. IC50 values are determined by linear interpolation between two bracketing points.
  • the agents of the invention inhibit steroid sulfatase with rel IC 50 values in the range 0.8 - 165, corresponding to absolute IC 50 values in the range 32 nM to 7800 nM.
  • the dosage to be used will vary, of course, depending e.g. on the particular agent employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the agents are administered at a daily dose of from about 0.1 mg/kg to about 100 mg/kg animal body weight, conveniently given in divided doses two to four times daily. For most large mammals the total daily dosage is from about 5 mg to about 5000 mg, conveniently administered, for example, in divided doses up to four times a day or in retarded form.
  • Unit dosage forms comprise, e.g. from about 1.25 mg to about 2000 mg of the agents in admixture with at least one solid or liquid pharmaceutically acceptable carrier or diluent.
  • the agents of the invention may be administered in similar manner to known standards for use in such indications.
  • the agents of the invention may be admixed with conventional, chemotherapeutically acceptable carriers and diluents and optionally further excipients, and administered e.g. orally e.g. in the form of formulations, e.g. in the form of tablets and capsules.
  • the agents may be administered topically, e.g. in the form of formulations, e.g. lotions, solutions, ointments or creams; or parenterally or intravenously.
  • concentration of active substance will of course vary, e.g. depending on the agent employed, the treatment desired and the nature of the form or formulation used. In general, satisfactory results are obtained in e.g. topical formulations at concentrations of from about 0.05 % to about 5 %, particularly from about 0.1 % to about 1 % by weight.
  • the invention therefore also provides:
  • an agent of the invention for use as a pharmaceutical, especially as a steroid sulfatase inhibitor
  • composition comprising an agent of the invention together with at least one pharmaceutically acceptable carrier or diluent;
  • the invention includes the agents of the invention for use in particular in the prevention or treatment of androgen-dependent disorders of the pilosebaceous unit, such as acne, seborrhea, androgenic alopecia and hirsutism, and in the topical treatment of squamous cell carcinoma, as well as for use in enhancement of cognitive function.
  • androgen-dependent disorders of the pilosebaceous unit such as acne, seborrhea, androgenic alopecia and hirsutism
  • squamous cell carcinoma as well as for use in enhancement of cognitive function.
  • the agents of the invention are particularly beneficial as regards side effect profile and chemical stability and thus well-suited for e.g. long term storage of topical galenical forms.
  • the compound of Example 12 namely sulfamic acid 2-(adamantan-2- ylidenemethyl)benzoxazol-6-yl ester, is the most preferred agent of the invention in the above indications. It has, for example, been determined that in the above assay 1., this agent has a rel IC 5 o value of 4.6 and an absolute IC 50 value of about 0.97 ⁇ M, and in the above assay 2., a rel IC 50 value of 1.25.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Benzoxa- and benzthiazoles substituted at the 2 position and carrying a sulfamic acid ester group bound via oxygen to the phenyl part of the ring structure, such as the compounds of formula (I) wherein the symbols have various significances, possess interesting pharmacological activity. They can be prepared by sulfamoylation of a corresponding compound carrying a hydroxy group on the phenyl part of the ring structure, or by N-substitution. They are indicated for use as steroid sulfatase inhibitors in the prevention and treatment of illnesses responsive to steroid sulfatase inhibition, such as acne.

Description

BENZOXA- AND BENZTHIAZOLES
The invention relates to benzoxa- and benzthiazole derivatives. It concerns a benzoxa- or benzthiazole substituted at the 2 position and carrying a sulfamic acid ester group bound via oxygen to the phenyl part of the ring structure, hereinafter briefly named "a compound of the invention".
More specifically, it concerns a compound of formula I
Figure imgf000002_0001
wherein
X is O or S;
Ri and R2 either independently are hydrogen or alkyl, or one is hydrogen and the other is acyl or alkoxycarbonyl; and R3 is alkyl; alkenyl; alkinyl; cycloalkyl; cycloalkenyl; aryl; acyl; cycloalkylalkyl; cycloalkylalkenyl, including cycloalkanylidenealkyl; cycloalkenylalkyl; arylalkyl; arylalkenyl; arylalkinyl; alkoxycarbonylaminoalkyl; hydroxycycloalkylalkyl; cycloalkanylidenec'ycloalkanylidenalkyl; heteroaryl; or heteroarylalkyl; in free form or salt form.
The sulfamoyloxy moiety in formula I is bound to the ring system in position 5 or 6, preferably 6.
Alkyl as a group Ri or R2 preferably is of 1 to 4 carbon atoms, it especially is methyl. Acyl as a group R! or R2 preferably is formyl or alkylcarbonyl of altogether 2 to 5 carbon atoms, it especially is acetyl. Alkoxycarbonyl as a group Ri or R2 preferably is of altogether 2 to 5 carbon atoms, it especially is methoxycarbonyl. In significance R3: alkyl as such or as part of a substituent such as cycloalkylalkyl includes (Cι.22)alkyl, e.g. (Cι-ι6)alkyl and (Cι^)alkyl; alkenyl as such or as part of a substituent such as cycloalkylalkenyl includes (C2.22)alkenyl, e.g. (C2-iό)alkenyl and (C2_ )alkenyl; when it is part of cycloalkanylidenealkyl the double bond is attached directly to the cycloalkyl moiety and thus the alkenyl part of such a cycloalkylalkenyl group is to be viewed as consisting of just one carbon atom; alkinyl as such or as part of a substituent such as arylalkinyl includes (C2-22)alkinyl; cycloalkyl as such or as part of a substituent such as cycloalkylalkyl or hydroxycycloalkylalkyl includes (C4.ι2)cycloalkyl, such as cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclododecanyl; it may be mono- or polycyclic, such as bridged cycloalkyl, as in adamantyl, hexahydro-2,5-methanopentalenyl; bicyclo[3.3.1]nonyl, or it may be cycloalkyl annexed to a second ring system, e.g. a second cycloalkyl, such as decalin (octahydronaphthyl), and includes spiro cycloalkyl, as in l,4-dioxa-spiro[4.5]decyl or l,5-dioxa-spiro[5.5]undecyl, whereby the cycloalkyl moiety and the annexed second ring system are unsubstituted or substituted with e.g up to 4, preferably one or two alkyl or alkoxy moieties of preferably 1 or 2 carbon atoms; when cycloalkyl is part of a substituent, there preferably is just one, but there may be up to two, mono- or polycyclic cycloalkyl moieties, as in e.g. dicyclohexylmethyl; cycloalkenyl as such or as part of cycloalkenylalkyl includes (C4.ι2)cycloalkenyl, such as cyclohexenyl; it may be polycyclic, as in e.g. decahydrophenanthrenyl, and may be substituted, e.g. with 1 to 3 (Cι-4)alkyl; aryl as such or as part of arylalkyl, arylalkenyl or arylalkinyl includes (C5.ι8)aryl, e.g. (C5-ι2)aryl, e.g. phenyl or tetrahydronaphthalinyl, and may be substituted by e.g. alkyl; there may be up to 3, preferably 1 aryl moiety when aryl is part of a substitutent, as in di- or triphenylmethyl; acyl includes the residue of a carboxylic acid, in particular an alkyl, aralkyl or aryl carboxylic acid, e.g. an alkyl, aralkyl or aryl carbocyclic acid; - cycloalkylalkenyl includes e.g. a cycloalkanylidenalkyl group of formula i
Figure imgf000004_0001
whe Xrein
R» is hydrogen or alkyL e.g.
Figure imgf000004_0002
especially methyl and
R5 and R$ together with the carbon atom to which they are attached form cycloalkyl;
- cycloalkenylalkyl is e.g. cyclohexenylmethyl;
- alkoxycarbonylaminoalkyl is e.g. tert-butoxycarbonylamino-2,2-dimethylpropyl;
- in hydroxycycloalkylalkyl the hydroxy group preferably is bound to the cycloalkyl part at the same carbon atom that is bound to the alkylene part of the hydroxycycloalkylalkyl moiety;
- cycloalkanylidenecycloalkanylidenalkyl is e.g. bicyclobutylidenylidenemethyl;
- heteroaryl as such or as part of heteroarylalkyl preferably is pyridyl or thienyl.
X preferably is oxygen. Ri and R2 preferably are hydrogen. R3 preferably is alkyl; cycloalkylalkyl; cycloalkenylalkyl; alkoxycarbonylaminoalkyl; or cycloalkylalkenyl, e.g. a group of formula i as defined above.
A subgroup of compounds of the invention is the compounds of formula I wherein X is as defined above; Ri and R2 are hydrogen; and R3 is alkyl, alkenyl, cycloalkyl or cycloalkenyl, in free form or salt form.
A further subgroup of compounds of the invention is the compounds of formula Is
Figure imgf000004_0003
wherein X, t, R5 and R$ are as defined above; in free form or salt form. A further subgroup of compounds of the invention is the compounds of formula It
Figure imgf000005_0001
wherein X, Ri, R2 and R4 are as defined above; in free form or salt form; e.g. sulfamic acid 2-(adamantan-2-ylidenemethyl)benzoxazol-6-yl ester in free form or salt form.
A further subgroup of compounds of the invention is the compounds of formula Ipi
Figure imgf000005_0002
wherein either Rιp and R2p have the significances indicated above for Ri and R2; and
R3pι is alkyl; alkenyl; alkinyl; cycloalkyl; acyl; cycloalkylalkyl; arylalkyl; arylalkenyl; arylalkinyl; heteroaryl; or heteroarylalkyl; or Rip and R2p are hydrogen; and R3pι is adamantan-2-ylidenemethyl; in free form or salt form.
A further subgroup is the compounds of formula Ip2
Figure imgf000005_0003
wherein
Ri and R2 are as defined above; and
R3p2 is alkyl; alkenyl; alkinyl; cycloalkyl; acyl; cycloalkylalkyl; adamantylalkenyl, including adamantanylidenalkyl; arylalkyl; arylalkenyl; arylalkinyl; heteroaryl; or heteroarylalkyl; in free form or salt form. A further subgroup is the compounds of formula Iq
Figure imgf000006_0001
wherein X is as defined above and R3q is:
- (C,.ι3)alkyl;
- (Cιo-i6)alkenyl;
- cycloalkyl selected from adamantyl and hexahydro-2-5-methano-pentalenyl;
- the cycloalkenyl moiety 7-isopropyl-l,4a-dimethyl-l,2,3,4,4a,4b,5,6,10,10a- decahydrophenanthren- 1-yl;
- an aryl moiety 5,6,7, 8-tetrahydronaphthalenyl;
- cycloalkyl selected from adamantylalkyl of 1 to 4 carbon atoms in the alkylene part thereof and dicyclohexylmethyl;
- cycloalkylalkenyl (including cycloalkanylidenalkyl) selected from: adamantanyliden(Cι-4)alkyl; (C4.ι2)cycloalkyliden(Cι-4)alkyl; bicyclo[3.3. ljnonylidenemethyl; dimethylcyclohexylidenemethyl; (Cι- )alkoxycyclohexylidenemethyl; (Cι_ )alkylcyclohexylidenemethyl; tetra(Cι-4)alkylcyclohexylidenemethyl; l,4-dioxaspiro[4.5]dec-8-ylidenemethyl; 3,3-dimethyl-l,5-dioxa-spiro[5.5]undec- 9-ylidenemethyl; and octahydronaphthalylidenemethyl;
- cyclohexenyl(Cι- )alkyl;
- arylalkyl selected from di- or triphenyl(Cι_4)alkyl;
- (Cι-4)alkoxycarbonylamino(Cι-6)alkyl;
- hydroxycycloalkylalkyl selected from: (2-hydroxyadamant-2-yl)(Cι-6)alkyl; (9-hydroxybicyclo[3.3. l]non-9-yl(Ci_ )alkyl; and
1 -hydroxy-2,2-dimethylcyclohexyl(Cι-4)alkyl; or
- a cycloalkanylidenecycloalkanylidenalkyl moiety bicyclobutylidenylidenemethyl; in free form or salt form.
A compound of the invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a solvated salt. A salt of a compound of the invention includes a pharmaceutically acceptable salt, e.g. an acid addition salt. A compound of the invention in free form may be converted into a corresponding compound in the form of a salt and vice versa. A compound of the invention in the form of a solvate in free form or salt form may be converted into a corresponding compound in free form or salt form in unsolvated form and vice versa.
A compound of the invention may exist in the form of isomers and mixtures thereof; e.g. a compound of the invention may contain substituents exhibiting geometric isomerism and/or asymmetrically substituted carbon atoms and may thus exist in the form of isomers and/or diastereoisomeres and mixtures thereof. Isomeric mixtures may be separated in conventional manner to obtain pure isomers or diastereoismers, respectively. The invention includes a compound of the present invention in any isomeric and/or diasteroisomeric pure form and in the form of any isomeric and/or diastereoisomeric mixture.
The invention further includes a process for the preparation of a compound of the invention as defined above, comprising sulfamoylating a corresponding benzoxa- or benzthiazole substituted in the 2 position and carrying a hydroxy group on the phenyl part of the ring structure.
More specifically, it concerns a process for the preparation of a compound of formula I as defined above, in free form or salt form, comprising a) when Ri and R are both hydrogen, sulfamoylating a compound a formula II
Figure imgf000007_0001
wherein X and R3 are as defined above, or b) when one or both of Ri and R2 are other than hydrogen, appropriately N-substituting a compound of formula I wherein Ri and R2 are both hydrogen, and recovering the resultant compound of formula I in free form or salt form.
The process of the invention may be effected in conventional manner. Process variant a) may be carried out e.g. by reacting a compound of formula II al) with sulfuryl chloride and sodium- or potassium azide, and reducing the azide group to an amino group -NH2 in a resultant compound of formula III
Figure imgf000008_0001
wherein X and R3 are as defined above; or a2) with Cl-SO2-NCO and submitting the product obtained to aqueous hydrolysis; or a3) with a compound of formula IV
Figure imgf000008_0002
wherein Ri and R2 are both hydrogen and L is a leaving group, e.g. halogen, preferably chloro; such as H2N-SO2Cl; e.g. in an inert solvent, e.g. dimethylformamide or dimethylacetamide, with or without addition of an organic base, such as an organic tertiary amine, or an inorganic base, e.g. an alkali(hydrogen)carbonate or alkali hydride, preferably sodium hydride.
Process variant b) may be effected by N-alkylating, N-acylating or N-alkoxycarbonylating using e.g. for N-alkylation activated alkyl, e.g. alkyl halogenides, such as alkyl iodides, alkyl sulfates or alkyl mesy(tosy)lates; for N-acylation acyl halogenides; and for N-alkoxycarbonylation alkoxycarbonyl halides, preferably chlorides. The reaction is effected conveniently in the presence of a suitable base, preferably an alkali metal carbonate or alkali metal hydride, preferably in an inert, preferably polar solvent such as acetone or dimethylformamide, at temperatures between about -20° and about +120°C, preferably between room temperature and about 60°C.
A resultant compound of the invention may be recovered from the reaction mixture and isolated and purified in conventional manner. Isomers, such as geometric isomers or enantiomers or diastereoisomers, may be obtained in conventional manner, e.g. by fractional crystallization or asymmetric synthesis from corresponding asymmetrically substituted, e.g. optically active starting materials. The starting materials may also be prepared in conventional manner. A compound of formula II may e.g. be obtained by α) reacting a compound of formula V
Figure imgf000009_0001
wherein X is as defined above, with a compound of formula R3-COHal, wherein Hal is halogen, e.g. chloro, and R3 is as defined above and, if desired, further reacting a resultant compound of formula II with sulfuryl chloride and sodium- or potassium azide to obtain a compound of formula III; or β) for the production of a compound of formula Ila
Figure imgf000009_0002
wherein X, R , R5 and Re are as defined above, reacting a compound of formula lib
Figure imgf000009_0003
wherein R* and X are as defined above, with a compound of formula VI
Figure imgf000009_0004
wherein R5 and R« are as defined above, e.g. in the presence of trimethylsilyl chloride (TMSCl), N-ethyldϋsopropylamine and sodium bis(trimethylsilyl)amide in an inert solvent, e.g. tetrahydrofurane, at low temperatures, e.g. around -70°C, and dehydrating a resultant compound of formula lie
Figure imgf000009_0005
wherein X, R4, R5 and Re are as defined above, e.g. by treatment with trifluoroacetic acid in an inert solvent such as toluene.
Process variant a3) above is also indicated for the preparation of a compound of formula I wherein Ri and R2 are hydrogen, X is as defined above and R3 is a group of formula i as defined above, starting from a corresponding compound of formula lie and dehydrating a resultant compound of formula I wherein R3 is hydroxycycloalkylalkyl as described under β) above.
Alternatively a compound of formula II may be obtained by reaction of a compound of formula V with a compound of formula R3COOH, conveniently in the presence of propylphosphonic acid anhydride and N-ethyl-diisopropylamine; or 2,2'-dithiopyridine and triphenylphosphane; preferably in an inert solvent, e.g. methylene chloride, and cyclizing a resultant compound of formula VII
Figure imgf000010_0001
wherein X and R3 are as defined above, e.g. in the presence of diethylazodicarboxylate and triphenylphosphine in an inert solvent, e.g. tetrahydrofurane, at e.g. room temperature. Alternatively a compound of formula Ila may be obtained by reaction of a compound of formula VIII
Figure imgf000010_0002
wherein X and R> are as defined above and Alk is alkyl, preferably methyl, with a compound of formula VI, e.g. in the presence of butyl lithium in an inert solvent, e.g. tetrahydrofurane, conveniently at low temperatures, such as around -70°C, to obtain a compound of formula IX
Figure imgf000011_0001
wherein Alk, X, R^ R5 and R are as defined above; and either
- dealkylating to obtain a compound of formula lie and then dehydrating, e.g. as described under β) above, to obtain a corresponding compound of formula Ila; or
- dehydrating first, e.g. as described under β) above, to obtain a compound of formula X
Figure imgf000011_0002
wherein Alk, X, >, R5 and Re are as defined above; and then dealkylating to obtain a corresponding compound of formula Ila, e.g. in the presence of pyridine and HCl, conveniently at high temperatures, such as above about 100°C, e.g. around 200°C.
Many starting materials and intermediates are either known or can be prepared according to known methods or analogously as described in the Examples.
The compounds of formula Ila, He, IX and X in free form or salt form are novel and also form part of the invention.
The following Examples illustrate the invention. Temperatures are in degrees Celsius. NMR values are for 13C-NMR spectra at 62.9 MHz in CDC13 unless indicated otherwise. The following abbreviations are used:
DMA = dimethylamide
DMSO = dimethylsulfoxide
Ex. = Example m.p. = melting point.
Example 1: Sulfamic acid 2-(adamantan-l-ylmethyl)benzoxazol-6-yl ester
[X = O; Ri = R2 = H; R3 = adamantan-1-ylmethyl; sulfamoyloxy moiety in position 6] [process variant a)] 74 mg 2,6-di-tert-butyl-4-methylpyridine and 83 mg amidosulfonyl chloride are added to a solution of 50 mg 2-(adamantan-l-ylmethyι)benzoxazol-6-ol (formula II) in 5 ml of a mixture of dichloromethane and dimethylformamide and the mixture obtained is stirred at room temperature for about 2 hours. The solvent is evaporated off and the residue obtained is purified by chromatography on silica gel (cyclohexane/ethyl acetate 2/1). The title compound is obtained (crystals; m.p. 147-150°); 13C-NMR: 166.556, 150.344, 147.020, 139.886, 119.423, 118.873, 105.526, 42.977, 42.300, 36.477, 33.977, 28.441.
Examples la and lb: Sulfamic acid 2-ri-(2-hydroxyadamantan-2-yl)pentvn- benzoxazol-6-yl ester and, respectively, sulfamic acid 2-ri-(adamantan-2-ylidene)pentyll- benzoxazol-6-yl ester
[X = O; Ri = R2= H; R3 = l-(2-hydroxyadamantan-2-yl)pentyl and, respectively, 1 -(adamantan-2-ylidene)pentyl; sulfamoyloxy moiety in position 6] [process variant a)] To a solution of 100 mg 2-[l-(2-hydroxyadamantan-2-yl)pentyl]benzoxazol-6-ol (formula II) in 2 ml of dry DMA is added 100 mg sulfamoyl chloride and the reaction mixture is stirred at about 60° for about 30 minutes. To the resultant mixture are added 6 ml of an aqueous sodium acetate solution (13.1 g in 60 ml) and 10 ml of ethyl acetate at room temperature and the mixture is stirred for a few minutes. The two phases formed are separated, the organic phase is washed with sodium acetate solution and brine and dried. From the dried solution the solvent is evaporated off and the residue obtained is purified by chromatography (silica gel; ethylacetate/cyclohexane 1/2). The title compound of Example la, and the title compound of Example lb, are obtained as oil; 13C-NMR:
- Example la: 170.909, 149.692, 146.899, 139.651, 119.899, 118.934, 105.730, 76.199,
44.068, 38.109, 37.509, 34.199, 33.774, 33.588, 32.876, 27.069, 26.965, 22.584, 13.848;
- Example lb: (125.8 MHz, de-DMSO) 166.091, 158.038, 149.590, 147.630, 119.957,
119.610, 116.214, 105.746, 39.393, 36.636, 35.022, 34.091, 31.971, 29.783, 27.643, 26.799, 22.203.
The following compounds of formula I are obtained in analogous manner using appropriate starting materials of formula II:
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
* 13C-NMR:
Example 8: 166.745, 155.558, 150.600, 149.648, 147.269, 120.358, 119.394, 105.693, 64.292, 57.866, 35.634, 28.333, 26.318, 14.102.
Example 12: 168.446, 146.658, 140.656, 119.420, 118.622, 105.099, 103.659, 41.770, 40.197, 39.233, 36.789, 33.951, 27.851.
Example 28: (125.8 MHz) 164.389, 160.842, 149.534, 146.796, 140.860, 119.638, 118.531, 110.406, 105.023, 38.294, 32.437, 30.581, 30.030, 22.869, 22.406, 13.866, 13.835.
Example 29: (125.8 MHz) 160.874, 146.784, 140.909, 119.643, 118.522, 110.396, 105.037, 38.574, 32.674, 31.955, 31.506, 28.017, 27.538, 22.460, 22.277, 13.919.
Example 30: (125.8 MHz) 160.924, 146.798, 140.770, 119.592, 118.590, 110.348, 105.036, 38.639, 32.736, 31.575, 29.427, 29.003, 28.333, 27.849, 22.529, 22.496, 14.006, 13.976.
Example 31: (125.8 MHz) 160.870, 146.764, 140.969, 119.653, 118.499, 110.392, 105.021, 38.609, 32.702, 31.736, 29.733, 29.298, 29.050, 28.378, 27.886, 22.614, 14.008.
Example 35: (125.8 MHz, αVDMSO) 167.336, 157.635, 154.176, 149.395, 132.640, 130.962, 123.041, 120.036, 118.927, 115.893.
Example 57: (dδ-DMSO) 165.887, 162.639, 151.553, 147.166, 134.719, 122.842, 121.308, 115.533, 110.953, 40.749, 38.615, 36.358, 33.594, 27.502. Starting materials and intermediates may be obtained as follows:
A) 2-(Adamantan-l-yhnethyl)benzoxazol-6-ol (formula II)
To a mixture of 424 mg 2-(adamantan-l-yI)-N-(2,4-dihydroxy- phenyl)acetamide (formula VII) and 1.18 g triphenylphosphane in 15 ml of dry tetrahydrofuran, 0.7 ml of diethyl azodicarboxylate (DEAD) are added dropwise. The mixture is stirred overnight at room temperature, the solvent evaporated off and the residue purified by chromatography. The title compound is obtained (m.p. 247-251°).
B) 2-tert-Butyl-benzoxa-,ol-6-ol (formula II)
A mixture of 1.01 ml of pivaloyl chloride, 808 mg 2,4-d ydroxyaniline hydrochloride (formula V) and 0.4 ml of pyridine is heated at about 210° for about 18 hours. The mixture obtained is dispersed in a mixture of cyclohexane and ethyl acetate and purified by chromatography. The title compound is obtained (m.p. 204-210°).
C) 2-(Adamantan-2-ylidenemethyl)benzoxazol-6-ol (formula Ha) and 2-(2-hydroxyadamantan-2-ylmethyl)benzoxazoI-6-ol (formula He)
To a solution of 6.6 g 2-methyl-benzoxazol-6-ol (formula lib) in 100 ml of dry tetrahydrofuran, cooled to 0°, N-ethyldiisopropylamine and trimethylsilyl chloride are added. The mixture is stirred at room temperature for about 2 hours, cooled to -78°, and sodium bis(trimethylsilyl)amide solution is added in portions. To the mixture obtained solid 2-adamantanone (formula VI) is added and the mixture is kept at -78° for about one hour. The reaction mixture is allowed to warm up to room temperature and is poured into 300 ml of 1 M NaHSO4 solution. The mixture is extracted with ethyl acetate and the organic layer is dried over sodium sulfate. The solvent is evaporated off and the residue is purified by chromatography. The above title compounds are obtained (m.p., respectively, 248-253° and 238-240°).
Alternatively, in order to maximize the yield of the first title compound above, the evaporation residue obtained is treated with 240 ml of toluene, 3.1 ml of trifluoroacetic acid are added, and the reaction mixture is heated at about 115° for about 7 hours and cooled. Crystallization occurs. The first title compound above is obtained in the form of a ciystalline salt with trifluoroacetic acid. This is recrystallized in ethanol. The compound in free form is obtained (m.p. 248-253°).
D) 2-(Adamantan-2-ylidenemethyI)benzothiazoI-5-ol (formula Ila)
300 mg 2-(5-methoxy-benzothiazol-2-ylmethyl)adamantan-2-ol (formula X) and 527 mg pyridine hydrochloride are heated at about 200° for about 30 minutes. The melt obtained is dissolved in 100 ml of ethyl acetate, the mixture is extracted with water, 2.5 M sodium acetate solution and brine, the organic phase dried and the solvent evaporated off. The evaporation residue obtained is subjected to chromatography. The title compound is obtained (m.p. 156-158°).
E) 2-(Cycloheptylidenemethyl)benzothiazol-5-ol (formula Ha)
By reacting 120 mg 2-(cycloheptylidenemethyl)-5-methoxybenzothiazole (formula X) as described under D) above, the title compound is obtained ( p. 105-120°).
Analogously as described under A) to E) above and using appropriate starting materials, the following compounds of formula II are obtained:
- 2-(2,2-Dimethylpropyl)benzoxazol-6-ol (m.p. 176-184°);
- 2-(Adamantan-l-yl)benzoxazol-6-ol (mp. 260-265°);
- 2-Tridecyl-benzoxazol-6-oI ( p. 72-73°);
- 2-(2^-Diphenylethyl)benzoxazol-6-ol (mp. 182-206°);
- 2-(2,2,2-TriphenyIethyl)benzoxazol-6-ol (mp. 150-155°);
- 2-Dicyclohexylmethyl-benzoxazol-6-ol (mp. 196-204°); [l-(6-Hyclroxy-benzoxazol-2-yl)-2^dimethylpropyl]carbamic acid tert-butyl ester (mp. 131-160°);
- 2-(Hexahydro-2^-methano-pentalen-3a-yl)benzoxazol-6-ol (nxp. 241-243°);
- 2-(7-Isopropyl ,4a-dimethyI-l^^,4,4a,4b 5,6,10,10a-decahydrophenanthren-l-yl)- benzoxazol-6-ol ( p. 90-95°);
- 2-(Cyclohexylidenemethyl)benzoxazol-6-ol (mp. 158-162°);
- 2-(Cyclobutylidenemethyl)benzoxazol-6-oI (m.p. 200-203°);
- 2-(Cyclopentylidenemethyl)benzoxazol-6-ol (mp. 168-172°); -(Cycloheptylidenemethyl)benzoxazol-6-ol (m.p. 141-142°); 2-(Cyclododecanylidenemethyι)benzoxazol-6-oI (m.p.155-157°); 2-(Bicyclo[3.3.1]non-9-ylidenemethyl)benzoxazol-6-ol (m.p. 221-223°); 2-(9-Hydroxy-bicyclo[3.3.1]non-9-ylmethyl)benzoxazol-6-ol (m.ρ. 221-223°); 2-(2,2-Dimethyl-cycIohexylidenemethyl)benzoxazol-6-ol (13C13-NMR [CDCl3/CD3OD]: 163.552, 162.497, 154.865, 150.599, 134.691, 119.197, 112.951, 106.621, 97.295, 41.928, 38.100, 27.979, 27.915, 26.931, 22.141);
2-(2-Methoxy-cyclohex-(Z)-ylidenemethyl)benzoxazol-6-ol (m.p. 157-160°); 2-(2-Methoxy-cyclohex-(E)-ylidenemethyl)benzoxazol-6-ol (m.p. 148-150°); 2-(4-Ethylcyclohexylidenemethyl)benzoxazol-6-ol (m.p. 137-139°); 2-(3,3,5,5-Tetramethylcyclohexylidenemethyl)benzoxazol-6-ol (m.p. 161 - 163 °) ; 2-(l,4-Dioxa-spiro[4.5]dec-8-ylidenemethyl)benzoxazol-6-ol (m.p. 154-156°); 2-(3,3-Dimethyl-l,5-dioxa-spiro[5,5]undec-9-ylidenemethyl)benzoxazol-6-ol (m.p. 194-196°);
2-[Octahydronaphthal-l-ylidenemethyl)benzoxazol-6-ol (m.p. 160-162°); 2-(2-Butylhex-l-ylidene)benzoxazol-6-ol (m.p. 76-80°);
2-(2-Pentylhept-l-ylidene)benzoxazol-6-ol : (13C-NMR [CDC-3/CD3OD]: 162.626, 158.774, 156.116, 151.451, 134.282, 119.369, 113.678, 111.164, 97.619, 39.046, 32.974, 32.458, 32.018, 28.723, 28.150, 22.974, 22.857, 14.188);
2-(2-Hexyloct-l-ylidene)benzoxazol-6-ol (13C-NMR [CDCl3/CD3OD; 125.8 MHz]: 162.307, 158.269, 154.347, 150.785, 135.067, 119.352, 113.021, 110.771, 97.518, 38.504, 32.597, 31.645, 31.576, 29.409, 28.981, 28.410, 27.883, 22.511, 13.979); 2-(2-Heptylnon-l,2-yIidene)benzoxazol-6-ol (13C-NMR [CDC-3/CD3OD]: 162.640, 158.877, 156.143, 151.466, 134.266, 119.355, 113.694, 111.165, 97.638, 39.091, 33.033, 32.283, 30.194, 29.800, 29.643, 29.563, 29.075, 28.495, 23.106, 14.256); 2-[l-(2-Hydroxyadamantan-2-yl)ethyl]benzoxazoI-6-ol: (13C-NMR [CDCyCD3OD]: 119.169, 112.873, 97.4021, 38.110, 37.333, 36.660, 34.264, 33.568, 33.126, 32.878, 32.681, 26.978, 12.195);
2-(l-Adamantan-2-ylidene-ethyl)benzoxazol-6-ol (oil);
2-[l-(2-Hydroxyadamantan-2-yl)pentyl]benzoxazol-6-ol (13C-NMR: 119.037, 113.029, 97.790, 31.204, 28.435, 26.423, 22.184, 13.797); -(l-Adamantan-2-ylidene-pentyl)benzoxazol-6-ol (oil); -(5,6,7,8-Tetrahydronaphthalin-l-yl)benzoxazol-6-ol (m.p. 120-122°); -(Cyclobutylidenemethyl)benzoxazol-5-ol (m.p. 169-170°); -(Bicyclobutylidene-(2E)-ylidenemethyl)benzoxazol-5-ol (oil) ; -(Cyclopentylidenemethyl)benzoxazol-5-ol (m.p. 174-175°); 2-(Cyclohexylidenemethyl)benzoxazol-5-ol (m.p. 144-145°); 2-(Cyclohex-l-enylmethyl)benzoxazol-5-ol (oil); 2-(Cycloheptylidenemethyl)benzoxazol-5-ol (m.p. 93-95°); 2-(Cyclododecanylidenemethyl)benzoxazol-5-ol (m.p. 170-172°); 2-(Bicyclo[3.3.1]non-9-ylidenemethyl)benzoxazol-5-ol (m.p. 177-178°); 2-(9-Hydroxy-bicycIo[3.3.1]non-9-ylmethyl)benzoxazol-5-ol (m.p. 218-219°); 2-(l-Hydroxy-2,2-dimethylcyclohexylmethyI)benzoxazol-5-ol (m.p. 166-168°); 2-(2,2-Dimethylcyclohexylidenemethyl)benzoxazol-5-ol (oil); 2-(2-Methoxycyclohex-(Z)-ylidenemethyl)benzoxazol-5-ol (13C-NMR; 125.8 MHz: 162.709, 155.743, 153.888, 144.335, 142.170, 113.849, 112.059, 110.422, 105.244, 73.709, 55.602, 33.297, 32.882, 28.577, 20.122);
2-(2-Methoxycyclohex-(E)-ylidenemethyl)benzoxazol-5-ol (m.p. 141-144°); 2-(4-Ethylcyclohexylidenemethyl)benzoxazol-5-ol (13C-NMR [CDCl3/CD3OD]: 165.203, 160.259, 155.998, 145.294, 142.867, 114.835, 111.739, 109.631, 105.497, 40.269, 38.948, 35.672, 34.921, 31.423, 30.305, 12.672);
2-(3,3,5,5-TetramethylcycIohexylidenemethyl)benzoxazol-5-ol (m.p. 138-139°); 2-(l,4-Dioxa-spiro[4.5]dec-8-ylidenemethyl)benzoxazol-5-ol (m.p. 160-162°); 2-(3,3-Dimethyl-l,5-dioxa-spiro[5.5]undec-9-ylidenemethyl)benzoxazol-5-ol: (m.p. 137-140°);
2-(Adamantan-2-ylidenmethyl)benzoxazol-5-ol (m.p. 160-162°); 2-[l-(2-Hydroxyadamantan-2-yl)ethyl]benzoxazol-5-ol (mp. 125-130°); 2-(l-Adamantan-2-yIidene-ethyl)benzoxazol-5-ol (oil); and 2-(Adamantan-2-ylidenmethyl)benzthiazol-6-ol (m.ρ. 289-293°). F) 2-(Adamantan-l-yl)-N-(2.4-dihvdroxy-phenyl)acetamide (formula VTD
1.05 ml of N-ethyl-diisopropylamine is added to a solution of 323 mg 2,4-dihydroxyaniline hydrochloride (formula V), 388 mg (adamantan-l-yl)acetic acid (formula R3COOH) and 1.2 ml of propylphosphonic anhydride (50 % in ethyl acetate) in 20 ml of dry dichloromethane at 0°. The mixture obtained is stirred for about 18 hours at room temperature and the solvent is evaporated off. The residue is dissolved in 50 ml of ethyl acetate and extracted with 1 M aqueous hydrochloric acid, saturated aqueous NaHCO3 solution and brine. The organic layer is dried and the solvent is evaporated off. The title compound is obtained (rap. 195-197°).
G) 2-(Adamantan-2-ylidene)-N-(2.4-dihvdroxyphenyl)acetamide (formula VIP
3.0 g (adamantan-2-ylidene)acetic acid (formula R3COOH), 5.91 g triphenylphosphane and 4.95 g dipyridyldisulfide, dissolved in 100 ml of dichloromethane, are stirred at room temperature overnight. To the mixture obtained, 5.13 ml of N-ethyl-diisopropylarnine and 4.83 g 2,4-dmydroxyaniline hydrochloride (formula V) are added and the mixture is stirred for about 24 hours, the solvent is evaporated off, the evaporation residue is dissolved in ethyl acetate and extracted with a saturated aqueous NaH2PO4 solution and brine. The organic layer is dried, the solvent is evaporated off and the residue is purified by chromatography. The title compound is obtained (rap. 166-169°).
The following compounds of formula VH are obtained in analogous manner as described under F) and G) above:
- N-(2,4-DmydroxyphenyI)-3 -dimethyl-butyramide: [Η-NMR (CDC13): 7.41 (s, IH), 6.78 (d, J = 8.5 Hz, IH), 6.49 (d, J = 2.7 Hz, IH), 6.34 (dd, J = 2.7 + 8.5 Hz, IH), 2.29 (s, 2H), 1.10 (s, 9H)];
- Adamantane- 1-carboxylic acid (2,4-dihydroxyphenyl)amide (mp. 108- 110°);
- Tetradecanoic acid (2,4-dihydiOxyphenyl)amide (mp. 110- 112°) ;
- N-(2,4-Dihydroxyphenyl)-3 -diphenyl-propionamide (mp. 206-208°);
- N-(2,4-Dihydroxyphenyl)-3 3-triphenyl-propionamide (mp. 234-235°);
- 2,2- Dicyclohexyl-N-(2,4-dihydroxyphenyl)acetamide ( p. 179-181°);
- [l-(2,4-Dmydroxy-phenylcart)amoyl)-2^-dimemylpropyl]carbamic acid ter -butyl ester (mp. 88-91°); Hexahydro-2,5-methano-pentalene-3a-carboxylic acid (2,4-dihydroxyphenyl)amide
(m.p. 204-206°);
7-Isopropyl-l,4a-dimethyl-1^2 ,4,4a,4b,5,6,10,10a-decahydrophenanthren-l-carboxylic acid (2,4-dihydroxyphenyl)amide ( p. 200-207°);
2-Cyclohexylidene-N-(2,4-dihydroxyphenyl)acetamide [1H-NMR (CDC13): 6.85 (d, J = 8.6 Hz, IH), 6.42 (d, J = 2.7 Hz, IH), 6.27 (dd, J = 2.7 + 8.6 Hz, IH), 5.69 (s, IH), 2.82 (bm, 2H), 2.16 (bm, 2H), 1.60 (s, 6H)]; and
5,6,7,8-Tetrahydronaphthalene-l-carboxylic acid (2,4-dihydroxyphenyI)-amide (m.p. 168-174°).
H) 2-(CvcIoheptan-2-ylidenemethvI)-5-methoxy-benzothiazole (formula X)
187 ul of methansulfonyl chloride are added to a mixture of 350 mg of 2-(5-methoxybenzothiazol-2-ylmethyl)cycloheptan-2-ol (formula IX), 665 ul of triethylamine and a catalytical amount of 4-N,N-d me ylaminopyridine in 12 ml of dry dichloromethane at about 0°. The mixture is stirred for about 12 hours at room temperature, 187 μl of methansulfonyl chloride and 665 μl of triethylamine are added and the resultant reaction mixture is stirred at about 40° for about 48 hours. The mixture is diluted with 100 ml of ethyl acetate and then extracted with 1 M aqueous hydrochloric acid, saturated aqueous sodium bicarbonate solution and brine. The organic phase is dried and the solvent is evaporated off. The residue is subjected to chromatography. The title compound is obtained [13C-NMR (125.8 MHz): 166.528, 158.978, 155.645, 154.597, 126.878, 121.337, 119.750, 114.743, 105.127, 55.561, 39.394, 33.143, 29.921, 29.344, 28.775, 26.435].
I) 2-(5-MethoxybenzothiazoI-2-ylmethyl)adamantan-2-ol (formula DO
2.5 ml of a 1.6 M n-butyllithium solution in hexane are added dropwise to a solution of 358 mg of 5-methoxy-2-methylbenzothiazole (formula VUI) in 5 ml of dry THF, cooled to about - 78° and the mixture obtained is stirred for about one hour. Solid 2-adamantanone (formula VI) is added and the mixture is kept at -78° for about one hour. The mixture is allowed to warm to room temperature and 400 μl of acetic acid are added. The resultant mixture is diluted with 60 ml of ethyl acetate and extracted with saturated NaH2PO solution. The solvent of the organic phase is evaporated off and the residue obtained is subjected to chromatography. The title compound is obtained (mp. 140-142°).
The following compounds of formula IX are obtained in analogous manner as described under I) above:
- 2-(5-Methoxy-benzothiazol-2-ylmethyl)cycloheptan-2-ol [13C-NMR (125.8 MHz): 169.841, 159.007, 154.324, 121.540, 115.095, 105.275, 75.529, 55.605, 46.163, 41.063, 29.655, 22.300]; and
- 2-(6-Methoxy-benzothiazol-2-ylmethyl)adamantan-2-ol (mp. 161-163°).
The compounds of the invention, in particular the compounds of formula I, in free form or pharmaceutically acceptable salt form, including as solvates, hereinafter briefly named "the agents of the invention", possess pharmacological activity. They are indicated for use as pharmaceuticals. In particular, they inhibit steroid sulfatase activity.
Steroidal hormones in particular tissues are associated with several diseases, such as tumors of the breast, endometrium and prostate. Important precursors for the local production of these steroid hormones are steroid 3-O-sulfates which are desulfated by the enzyme steroid sulfatase in the target tissues. Inhibition of this enzyme results in therapeutically relevant, reduced local levels of the corresponding active steroidal hormones. Furthermore, steroid sulfatase inhibitors may also be immunosuppressive, and enhance memory when delivered to the brain.
The agents of the invention reduce endogenous levels of androgens and/or estrogens in skin and are thus particularly indicated for use in the prevention or treatment of androgen- dependent disorders of the pilosebaceous unit, such as acne, seborrhea, androgenic alopecia and hirsutism, and in the topical treatment of squamous cell carcinoma. The agents of the invention are therefore indicated for use as steroid sulfatase inhibitors, particularly in the prevention and treatment of illnesses responsive to steroid sulfatase inhibition, such as illnesses in which the steroid products of sulfatase cleavage play a role, in particular in the prevention and treatment of the following specific conditions: androgen- dependent disorders of the pilosebaceous unit such as acne, seborrhea, androgenic alopecia and hirsutism; cancer, especially estrogen- and androgen-dependent tumors such as tumors of the breast, endometrium and prostate, and squamous cell carcinoma; inflammatory and autoimmune diseases such as rheumatoid arthritis, type I and II diabetes, systemic lupus erythematosus, multiple sclerosis, myastenia gravis, thyroiditis, vasculitis, ulcerative colitis and Crohn's disease; skin disorders such as psoriasis, eczema and contact dermatitis; graft versus host disease; asthma; organ rejection following transplantation; and for enhancement of cognitive function, as in senile dementia, including Alzheimer's disease, by increasing DHEAS (dehydroepiandrosterone) levels in the central nervous system.
The above activities can be shown e.g. in the following assays: 1. Steroid sulfatase inhibition in vitro:
Human steroid sulfatase is obtained in pure form as described in WO 99/52890 and the assay is effected as follows:
Purified human steroid sulfatase not only is capable of cleaving steroid sulfates, but also readily cleaves aryl sulfates, such as p-nitrocatechol sulfate which is used herein. Assay mixtures are prepared by consecutively dispensing the following solutions into the wells of flat-bottom micro titer plates:
1) 50 μl inhibitor dilution in buffer (= 0.1 M Tris-HCl, ph 7.5, 0.1 % Triton X-100);
2) 50 μl substrate (= 20 mM p-nitrocatechol sulfate in buffer)
3) 50 μl enzyme dilution to give a final concentration of 75 nM steroid sulfatase.
Plates are incubated at 37°C for 30 minutes. The assay is stopped by addition of 100 μl of 1 N NaOH, and optical density measured in a microplate reader at 492 nm. Compounds are added from stock solutions in ethanol; the final ethanol concentration does not exceed 0.1 %. IC50 values are calculated by nonlinear regression of the concentration/optical density data using the program Grafit (Erithacus Ltd.). Reported values are the result of three determinations. From the fluorescence intensity data (I) obtained at different concentrations (c) of the test compound, the concentration inhibiting the enzymatic activity by 50 % (IC50) is calculated using the equation
Figure imgf000028_0001
I = l + (c / IC50)s wherein I100 is the intensity observed in the absence of inhibitor and s is the slope factor.
Estrone-3-O-sulfamate serves as reference compound and its IC50 value is determined in parallel to the test compounds and is about 60 nM. Relative IC50 values (rel IC50) are defined as follows:
IC50 of test compound rel lCso =
IC50 of estrone sulfamate
The agents of the invention inhibit steroid sulfatase in this assay with rel IC50 values in the range of about 0.1 to 30.
2. Steroid sulfatase inhibition in the CHO/STS assay:
CHO cells stably transfected with human steroid sulfatase (CHO/STS) are seeded into microtiter plates. After reaching approximately 90% confluency, they are incubated overnight with graded concentrations of test substances. They are then fixed with 4 % paraformaldehyde for 10 minutes at room temperature and washed 4 times with PBS before incubation with 100 μl/well 0.5 mM 4-methylumbelliferyl sulfate (MUS) dissolved in 0.1M Tris-HCl, pH 7.5. The enzyme reaction is carried out at 37°C for one hour. Then 50 μl/well stop solution (1M Tris-HCl, pH 10.4) are added. The enzyme reaction solutions are transferred to white plates (Microfluor, Dynex, Chantilly, VA, USA) and read in a Fluoroskan II fluorescence microtiter plate reader. Reagent blanks are subtracted from all values. For drug testing, the fluorescence units (FU) are divided by the optical density readings after staining cellular protein with sulforhodamine B (OD550) in order to correct for variations in cell number. IC50 values are determined by linear interpolation between two bracketing points. In each assay with inhibitors, estrone 3-O-sulfamate is run as a reference compound, and the IC50 values are normalized to estrone 3-O-sulfamate: relative IC50 = IC50 compound / IC50 estrone 3-O-sulfamate. In this assay the agents of the invention inhibit steroid sulfatase with rel IC50 values in the range 0.8 - 165, corresponding to absolute IC50 values in the range 32 nM to 7800 nM.
For the above use in steroid sulfatase inhibition the dosage to be used will vary, of course, depending e.g. on the particular agent employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the agents are administered at a daily dose of from about 0.1 mg/kg to about 100 mg/kg animal body weight, conveniently given in divided doses two to four times daily. For most large mammals the total daily dosage is from about 5 mg to about 5000 mg, conveniently administered, for example, in divided doses up to four times a day or in retarded form. Unit dosage forms comprise, e.g. from about 1.25 mg to about 2000 mg of the agents in admixture with at least one solid or liquid pharmaceutically acceptable carrier or diluent.
The agents of the invention may be administered in similar manner to known standards for use in such indications. The agents of the invention may be admixed with conventional, chemotherapeutically acceptable carriers and diluents and optionally further excipients, and administered e.g. orally e.g. in the form of formulations, e.g. in the form of tablets and capsules.
Alternatively, the agents may be administered topically, e.g. in the form of formulations, e.g. lotions, solutions, ointments or creams; or parenterally or intravenously. The concentration of active substance will of course vary, e.g. depending on the agent employed, the treatment desired and the nature of the form or formulation used. In general, satisfactory results are obtained in e.g. topical formulations at concentrations of from about 0.05 % to about 5 %, particularly from about 0.1 % to about 1 % by weight.
The invention therefore also provides:
- an agent of the invention for use as a pharmaceutical, especially as a steroid sulfatase inhibitor;
- a pharmaceutical composition comprising an agent of the invention together with at least one pharmaceutically acceptable carrier or diluent;
- a process for the preparation of a pharmaceutical composition having an agent of the invention together with at least one pharmaceutically acceptable carrier or diluent, comprising mixing an agent of the invention together with at least one pharmaceutically acceptable carrier or diluent;
- a method of prevention or treatment of illnesses responsive to steroid sulfatase inhibition comprising administering a therapeutically effective amount of an agent of the invention to a subject in need of such treatment; and
- the use of an agent of the invention in the preparation of a medicament for prevention or treatment of illnesses responsive to steroid sulfatase inhibition.
The invention includes the agents of the invention for use in particular in the prevention or treatment of androgen-dependent disorders of the pilosebaceous unit, such as acne, seborrhea, androgenic alopecia and hirsutism, and in the topical treatment of squamous cell carcinoma, as well as for use in enhancement of cognitive function.
The agents of the invention are particularly beneficial as regards side effect profile and chemical stability and thus well-suited for e.g. long term storage of topical galenical forms.
The compound of Example 12, namely sulfamic acid 2-(adamantan-2- ylidenemethyl)benzoxazol-6-yl ester, is the most preferred agent of the invention in the above indications. It has, for exemple, been determined that in the above assay 1., this agent has a rel IC5o value of 4.6 and an absolute IC50 value of about 0.97 μM, and in the above assay 2., a rel IC50 value of 1.25.

Claims

Claims:
1. A benzoxa-or benzthiazole substituted at the 2 position and carrying a sulfamic acid ester group bound via oxygen to the phenyl part of the ring structure.
2. A compound of formula I
Figure imgf000031_0001
wherein
X is O or S;
Ri and R2 either independently are hydrogen or alkyl, or one is hydrogen and the other is acyl or alkoxycarbonyl; and R3 is alkyl; alkenyl; alkinyl; cycloalkyl; cycloalkenyl; aryl; acyl; cycloalkylalkyl; cycloalkylalkenyl, including cycloalkanylidenealkyl; cycloalkenylalkyl; arylalkyl; arylalkenyl; arylalkinyl; alkoxycarbonylaminoalkyl; hydroxycycloalkylalkyl; cycloalkanylidenecycloalkanylidenalkyl; heteroaryl; or heteroarylalkyl; in free form or salt form.
3. A compound according to claim 1 or 2 of formula Ipi
Figure imgf000031_0002
wherein either
Rip and R2p have the significances indicated in claim 2 for Ri and R2; and
R3pι is alkyl; alkenyl; alkinyl; cycloalkyl; acyl; cycloalkylalkyl; arylalkyl; arylalkenyl; arylalkinyl; heteroaryl; or heteroarylalkyl; or Rip and R2p are hydrogen; and R3pι is adamantan-2-ylidenemethyl; or of formula Ip2
Figure imgf000032_0001
wherein
Ri and R2 are as defined in claim 2; and
R3p2 is alkyl; alkenyl; alkinyl; cycloalkyl; acyl; cycloalkylalkyl; adamantylalkenyl, including adamantanylidenalkyl; arylalkyl; arylalkenyl; arylalkinyl; heteroaryl; or heteroarylalkyl; in free form or salt form.
4. Sulfamic acid 2-(adamantan-2-ylidenemethyl)benzoxazol-6-yl ester in free form or salt form.
5. A process for the preparation of a compound according to claim 1 or 2, comprising sulfamoylating a corresponding benzoxa- or benzthiazole substituted in the 2 position and carrying a hydroxy group on the phenyl part of the ring structure, specifically, for the preparation of a compound of formula I as defined in claim 2, in free form or salt form, comprising a) when Ri and R2 are both hydrogen, sulfamoylating a compound a formula II
Figure imgf000032_0002
wherein X and R3 are as defined in claim 2, or
b) when one or both of Ri and R2 are other than hydrogen, appropriately N-substituting a compound of formula I wherein Ri and R2 are both hydrogen, and recovering the resultant compound in free form or salt form.
6. A compound of formula Ila
Figure imgf000033_0001
wherein
X is as defined in claim 2;
R* is hydrogen or alkyl; and
R5 and Re together with the carbon atom to which they are attached form cycloalkyl;
or of formula He
Figure imgf000033_0002
wherein X is as defined in claim 2 and Rj, R5 and Re are as defined in this claim;
or of formula IX
Figure imgf000033_0003
wherein X is as defined in claim 2, Alk is alkyl and t, R5 and Re are as defined in this claim;
or of formula X
Figure imgf000033_0004
wherein X is as defined in claim 2 and Alk, Rj, R5 and R$ are as defined in this claim; in free form or salt form. -33-
7. A compound according to claim 1 or 2 in free form or pharmaceutically acceptable salt form for use as a pharmaceutical.
8. A pharmaceutical composition comprising a compound according to claim 1 or 2 in free form or pharmaceutically acceptable salt form together with at least one pharmaceutically acceptable carrier or diluent.
9. A process for the preparation of a pharmaceutical composition comprising mixing a compound according to claim 1 or 2 in free form or pharmaceutically acceptable salt form together with at least one pharmaceutically acceptable carrier or diluent.
10. A method of prevention or treatment of illnesses responsive to steroid sulfatase inhibition comprising administering a therapeutically effective amount of a compound according to claim 1 or 2 in free form or pharmaceutically acceptable salt form to a patient in need of such treatment.
PCT/EP2000/011475 1999-11-19 2000-11-17 Benzoxa- and benzthiazoles WO2001036398A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/130,567 US6716865B1 (en) 1999-11-19 2000-11-17 Benzoxa- and benzthiazoles
AT00981270T ATE269853T1 (en) 1999-11-19 2000-11-17 BENZOXA AND BENZTHIAZOLYL SULFAMATES AND THEIR USE AS STEROID SULFATASE INHIBITORS
EP00981270A EP1230227B1 (en) 1999-11-19 2000-11-17 Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors
DE60011801T DE60011801T2 (en) 1999-11-19 2000-11-17 BENZOXA AND BENZTHIAZOLYL SULFAMATE AND THEIR USE AS STEROID-SULFATASE INHIBITORS
JP2001538887A JP2003514806A (en) 1999-11-19 2000-11-17 Benzoxa- and benzothiazoles
AU18577/01A AU1857701A (en) 1999-11-19 2000-11-17 Benzoxa- and benzthiazoles
HK02109307.7A HK1049329B (en) 1999-11-19 2002-12-23 Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9927439.1 1999-11-19
GBGB9927439.1A GB9927439D0 (en) 1999-11-19 1999-11-19 Organic compounds
GB0007511A GB0007511D0 (en) 2000-03-28 2000-03-28 Organic compounds
GB0007511.9 2000-03-28

Publications (1)

Publication Number Publication Date
WO2001036398A1 true WO2001036398A1 (en) 2001-05-25

Family

ID=26243976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011475 WO2001036398A1 (en) 1999-11-19 2000-11-17 Benzoxa- and benzthiazoles

Country Status (15)

Country Link
US (1) US6716865B1 (en)
EP (1) EP1230227B1 (en)
JP (1) JP2003514806A (en)
AR (1) AR026504A1 (en)
AT (1) ATE269853T1 (en)
AU (1) AU1857701A (en)
CO (1) CO5261573A1 (en)
DE (1) DE60011801T2 (en)
DK (1) DK1230227T3 (en)
ES (1) ES2223620T3 (en)
HK (1) HK1049329B (en)
PE (1) PE20011012A1 (en)
PT (1) PT1230227E (en)
TR (1) TR200402432T4 (en)
WO (1) WO2001036398A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043968A1 (en) * 2002-11-14 2004-05-27 Novartis Ag N-sulfonylaminothiazole
EP1430933A3 (en) * 2002-12-20 2004-09-29 Henkel Kommanditgesellschaft auf Aktien Cosmetic and pharmaceutical compositions comprising steroid sulfatase inhibitors and their use for the reduction of hair loss
WO2009037539A2 (en) 2007-09-17 2009-03-26 Preglem S.A. Treatment of oestrogen dependant conditions in pre-menopausal women
EP2540727A1 (en) * 2007-08-02 2013-01-02 Millennium Pharmaceuticals, Inc. Sulfamoylating reagent

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926730B (en) * 2014-03-21 2017-07-21 中国科学院武汉岩土力学研究所 A kind of Rosin-based Imidazoline class compound and its synthetic method and application
US11001564B2 (en) * 2016-09-13 2021-05-11 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472418A (en) * 1983-04-22 1984-09-18 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
WO1999027935A1 (en) * 1997-12-04 1999-06-10 Sterix Limited Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868800A (en) 1954-10-13 1959-01-13 Upjohn Co 6-ethoxybenzothiazole-2-sulfonamide
FI91869C (en) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Process for the preparation of benzoxazole derivatives as antidiabetic agents
US5273993A (en) 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
PT94305B (en) * 1989-06-12 1997-02-28 Robins Co Inc A H METHOD FOR PREPARING COMPOUNDS HAVING ONE OR MORE USED AMINOSULFONYLOXIDE RADIATIONS AS PHARMACEUTICAL PRODUCTS
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2124329C (en) 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
ATE188379T1 (en) 1992-10-14 2000-01-15 Merck & Co Inc FIBRINOGEN RECEPTOR ANTAGONISTS
ATE248153T1 (en) 1994-10-12 2003-09-15 Euro Celtique Sa NEW BENZOXAZOLES
US6169085B1 (en) * 1995-03-10 2001-01-02 G. D. Searle & Company Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
US5709845A (en) 1996-05-13 1998-01-20 Rajagopalan; Raghavan Tricyclic functional dyes for contrast enhancement in optical imaging
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
JPH10237053A (en) 1997-02-24 1998-09-08 Sumitomo Chem Co Ltd Production of benzothiazoles
US6140051A (en) 1997-07-21 2000-10-31 Promega Biosciences, Inc. Fluorescent dibenzazole derivatives and methods related thereto
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
AR019678A1 (en) 1998-06-18 2002-03-13 Novartis Ag ORGANIC COMPOUNDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472418A (en) * 1983-04-22 1984-09-18 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
WO1999027935A1 (en) * 1997-12-04 1999-06-10 Sterix Limited Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOO L W L ET AL: "Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 7, 26 March 1998 (1998-03-26), pages 1068 - 1083, XP002162181 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043968A1 (en) * 2002-11-14 2004-05-27 Novartis Ag N-sulfonylaminothiazole
JP2006507321A (en) * 2002-11-14 2006-03-02 ノバルティス アクチエンゲゼルシャフト N-sulfonylaminothiazole
EP1430933A3 (en) * 2002-12-20 2004-09-29 Henkel Kommanditgesellschaft auf Aktien Cosmetic and pharmaceutical compositions comprising steroid sulfatase inhibitors and their use for the reduction of hair loss
EP2540727A1 (en) * 2007-08-02 2013-01-02 Millennium Pharmaceuticals, Inc. Sulfamoylating reagent
US8933225B2 (en) 2007-08-02 2015-01-13 Millennium Pharmaceuticals, Inc. Process for the synthesis of E1 activating enzyme inhibitors
US9802938B2 (en) 2007-08-02 2017-10-31 Millennium Pharmaceuticals, Inc. Sulfamoylating reagents
US10745404B2 (en) 2007-08-02 2020-08-18 Millennium Pharmaceuticals, Inc. Process for the synthesis of E1 activating enzyme inhibitors
WO2009037539A2 (en) 2007-09-17 2009-03-26 Preglem S.A. Treatment of oestrogen dependant conditions in pre-menopausal women

Also Published As

Publication number Publication date
HK1049329A1 (en) 2003-05-09
TR200402432T4 (en) 2004-12-21
AR026504A1 (en) 2003-02-12
AU1857701A (en) 2001-05-30
PE20011012A1 (en) 2001-10-02
EP1230227B1 (en) 2004-06-23
US6716865B1 (en) 2004-04-06
HK1049329B (en) 2005-03-24
JP2003514806A (en) 2003-04-22
DK1230227T3 (en) 2004-08-16
ATE269853T1 (en) 2004-07-15
DE60011801T2 (en) 2005-07-14
EP1230227A1 (en) 2002-08-14
ES2223620T3 (en) 2005-03-01
CO5261573A1 (en) 2003-03-31
PT1230227E (en) 2004-10-29
DE60011801D1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
Lu et al. Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2, 6-dichlorobenzyloxy) phenyl thiazole, oxazole and imidazole derivatives. Part 2
Dogan et al. Synthesis of new 2, 5-disubstituted-1, 3, 4-thiadiazoles and preliminary evaluation of anticonvulsant and antimicrobial activities
Mavrova et al. Antihelminthic activity of some newly synthesized 5 (6)-(un) substituted-1H-benzimidazol-2-ylthioacetylpiperazine derivatives
DE69812159T2 (en) DERIVATIVES OF ADAMANTAN
EP1446115B1 (en) Cyanoalkylamino derivatives as protease inhibitors
CZ287209B6 (en) Amidine derivatives, process of their preparation and pharmaceutical preparations containing thereof
AU2008257323A1 (en) Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
JP2016147807A (en) Hydroxamic acid derivative and salt thereof
WO1996034856A1 (en) 2-ureido-benzamide derivatives
EP0399422A1 (en) Benzocycloalkane derivatives and production thereof
EP1230227B1 (en) Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors
EP0979823A1 (en) Novel amide compounds and drugs containing the same
US5183818A (en) Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme activity
US3726875A (en) 1,3(2h,4h)-dioxoisoquinoline-4-carboxylate esters and process therefor
US6362208B1 (en) Anilide compounds and drugs containing the same
EP0735029B1 (en) Benzothiazole derivatives
US5326883A (en) Oxime ether derivatives having lipoxygenase inhibitory activity
US4757078A (en) Cyclic aryl hydroxamic acids, derivatives thereof and method of use as anti-allergy agents
RU2048466C1 (en) Derivatives of quinoline-2-yl-methoxybenzylhydroxyurea, method of synthesis and 4-(quinoline-2-yl-methoxy)phenyl-cycloalkylketone as a parental compound for synthesis of quinoline-2-yl-methoxybenzylhydroxyurea derivatives
DD232045A5 (en) PROCESS FOR PREPARATION OF PRECIPITATES DEEP-REDUCING OXICAME
US3707485A (en) 2-(5-nitro-furyl-2)-5-aminoethoxy pyrimidines
HU190497B (en) Process for producing pyridyl-alkyl-nitrates and compositions containing them
EP1851209A2 (en) [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular
JP2967231B2 (en) 1,4-thiazine derivatives
Kumar et al. Synthesis of novel 1, 3, 4-oxadiazole analogues with expected antibacterial activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000981270

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 538887

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10130567

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000981270

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000981270

Country of ref document: EP